gyki 52466 has been researched along with Status Epilepticus in 2 studies
GYKI 52466: an AMPA (non-NMDA) receptor antagonist; structure given in first source
Status Epilepticus: A prolonged seizure or seizures repeated frequently enough to prevent recovery between episodes occurring over a period of 20-30 minutes. The most common subtype is generalized tonic-clonic status epilepticus, a potentially fatal condition associated with neuronal injury and respiratory and metabolic dysfunction. Nonconvulsive forms include petit mal status and complex partial status, which may manifest as behavioral disturbances. Simple partial status epilepticus consists of persistent motor, sensory, or autonomic seizures that do not impair cognition (see also EPILEPSIA PARTIALIS CONTINUA). Subclinical status epilepticus generally refers to seizures occurring in an unresponsive or comatose individual in the absence of overt signs of seizure activity. (From N Engl J Med 1998 Apr 2;338(14):970-6; Neurologia 1997 Dec;12 Suppl 6:25-30)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Benzodiazepines such as diazepam may fail to effectively treat status epilepticus because benzodiazepine-sensitive GABA(A) receptors are progressively internalized with continued seizure activity." | 7.76 | Treatment of early and late kainic acid-induced status epilepticus with the noncompetitive AMPA receptor antagonist GYKI 52466. ( Fritsch, B; Joelle Donofrio, J; Rogawski, MA; Stott, JJ, 2010) |
| "Benzodiazepines such as diazepam may fail to effectively treat status epilepticus because benzodiazepine-sensitive GABA(A) receptors are progressively internalized with continued seizure activity." | 3.76 | Treatment of early and late kainic acid-induced status epilepticus with the noncompetitive AMPA receptor antagonist GYKI 52466. ( Fritsch, B; Joelle Donofrio, J; Rogawski, MA; Stott, JJ, 2010) |
| "Kainic acid (KA) has long been used in experimental animals to induce status epilepticus (SE)." | 3.70 | [31P]/[1H] nuclear magnetic resonance study of mitigating effects of GYKI 52466 on kainate-induced metabolic impairment in perfused rat cerebrocortical slices. ( Liachenko, S; Melick, JA; Tang, P; Xu, Y, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fritsch, B | 1 |
| Stott, JJ | 1 |
| Joelle Donofrio, J | 1 |
| Rogawski, MA | 1 |
| Tang, P | 1 |
| Liachenko, S | 1 |
| Melick, JA | 1 |
| Xu, Y | 1 |
2 other studies available for gyki 52466 and Status Epilepticus
| Article | Year |
|---|---|
Treatment of early and late kainic acid-induced status epilepticus with the noncompetitive AMPA receptor antagonist GYKI 52466.
Topics: Animals; Anticonvulsants; Behavior, Animal; Benzodiazepines; Blood Pressure; Diazepam; Disease Model | 2010 |
[31P]/[1H] nuclear magnetic resonance study of mitigating effects of GYKI 52466 on kainate-induced metabolic impairment in perfused rat cerebrocortical slices.
Topics: Adenosine Triphosphate; Animals; Anti-Anxiety Agents; Anticonvulsants; Aspartic Acid; Benzodiazepine | 1998 |